Mekary Wissam, Vijayvargiya Sonya, Mouawad Celine, Bhatia Neal K, Shah Anand D, Westerman Stacy B, Lloyd Michael S, Leal Miguel A, Merchant Faisal M, El-Chami Mikhael F
Division of Cardiology, Section of Electrophysiology, Emory University School of Medicine, Atlanta, Georgia, USA.
J Cardiovasc Electrophysiol. 2025 Aug;36(8):1836-1840. doi: 10.1111/jce.16740. Epub 2025 May 23.
The AVEIR leadless pacemaker (LP) is a novel device that can function as a single atrial/ventricular or dual-chamber pacemaker. The introduction of single-chamber atrial LP has allowed electrophysiologists to treat patients with sinus node dysfunction with this device instead of implanting a dual-chamber transvenous pacemaker.
We retrospectively identified all patients who underwent AVEIR LPs' implantation at Emory Healthcare between 2022 and 2025. Baseline characteristics, indications for pacing, and procedure outcomes were retrieved from electronic medical records. The device's electrical characteristics were reported from routine interrogations done at our device clinic.
Between 2022 and 2025, 89 patients underwent implantation of 37 single-chamber atrial AVEIR, 34 single-chamber ventricular AVEIR, and 18 dual-chamber devices. Patients were followed for a median duration of 4.7 months [2;9]. The rate of major complications was 3.4% and minor complications 1.1%. Two patients with ventricular LP required upgrade to cardiac resynchronization therapy-defibrillator (CRT-D) due to pacing-induced cardiomyopathy (2.3%). One patient (2.7%) with a standalone atrial LP developed atrial fibrillation with slow ventricular response requiring the addition of a ventricular LP 10 months postimplantation.
In our center, we adopted a modular pacing approach for leadless pacing. This strategy focuses on minimizing the amount of hardware in the heart. This reduces complications such as perforation and dislodgment while optimizing battery longevity, which is affected by i2i communication.
AVEIR无导线起搏器（LP）是一种新型设备，可作为单腔心房/心室或双腔起搏器发挥作用。单腔心房LP的引入使电生理学家能够使用该设备治疗窦房结功能障碍患者，而无需植入双腔经静脉起搏器。
我们回顾性确定了2022年至2025年期间在埃默里医疗中心接受AVEIR LP植入的所有患者。从电子病历中获取基线特征、起搏指征和手术结果。该设备的电气特性来自我们设备诊所进行的常规问询报告。
2022年至2025年期间，89例患者接受了植入，其中包括37个单腔心房AVEIR、34个单腔心室AVEIR和18个双腔设备。患者的中位随访时间为4.7个月[2；9]。主要并发症发生率为3.4%，次要并发症发生率为1.1%。两名植入心室LP的患者因起搏诱发的心肌病需要升级为心脏再同步治疗除颤器（CRT-D）（2.3%）。一名植入独立心房LP的患者（2.7%）在植入后10个月出现房颤伴缓慢心室反应，需要增加一个心室LP。
在我们中心，我们采用了模块化起搏方法进行无导线起搏。该策略侧重于尽量减少心脏内的硬件数量。这减少了诸如穿孔和脱位等并发症，同时优化了受i2i通信影响的电池寿命。
